CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
|Articles|May 23, 2007
Career Opportunities in Regulatory Affairs
Author(s)BioPharm International Editors
Shire's Human Genetic Therapies team, based in Cambridge, MA, specializes in discovering, developing, and commercializing protein therapeutics primarily for the treatment of genetic diseases.
Advertisement
Shire's Human Genetic Therapies team, based in Cambridge, MA, specializes in discovering, developing, and commercializing protein therapeutics primarily for the treatment of genetic diseases. Opportunities are now available for the following:
- Senior Manager, CMC Regulatory Affairs
- Senior Director, CMC Regulatory Affairs
- Manager, International Regulatory Affairs
- Manager, International Regulatory Operations
- Senior Technical Writer
- Senior Technical Writing Consultant
- Regulatory Documentation Specialist II
For more info click
Advertisement
Related to this article
AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.
FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
Three case studies show how automated Raman plate reading can triage samples before chromatography in bioprocess development.
This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
Advertisement
Advertisement
Trending on BioPharm International
1
Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates
2
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
3
Samsung Biologics Secures 97.66% of PolyPeptide Shares in Tender Offer
4
Resolving the Speed-Specificity Trade-Off in Biopharma High-Throughput Screening
5